Smital Shah brings engineering, consulting, and finance experience earned at heavyweights like JP Morgan, Leerink, and Gilead to her role at ProQR Therapeutics. On Business of Biotech, Smital shares her recipe for successful business and finance operations in an emerging biopharma organization. Listen now and subscribe so you never miss an episode.
By Don Davis, Ph.D., president and principal, 5280 Life Sciences Consulting, LLC
Software tools and their supporting hardware can undoubtedly enable greater performance within your medical device business. Regardless of the type of technology implementation, how you select technology and how you implement it are two critical factors for any organization.
White Paper |
By Oliver Stauffer,PTI Packaging and Inspection Systems
The dye ingress test method continues to be a widely used test method for container closure integrity (CCI) within the pharmaceutical industry. Even with recent research attempting to support its use, this paper explains why the dye ingress test method is not a suitable approach.
When it comes to outsourcing in medical device manufacturing, companies are faced with decision to either use a selection of unrelated services providers or a single-source contract manufacturer that can handle every step of the process.
It is a constant challenge to keep improving product value for customers while reducing overall costs. Part of the solution resides in the functional activities of the risk involved and the cost of quality management. This article discusses finding the ideal balance of where risk and cost of quality meet.
Check out this on-demand webinar to discover how life science manufacturers can achieve this vision to adjust for new products, ramp up production, lower commissioning, and optimize their operation with quality and consistency.